Literature DB >> 21601230

Ion channel activity of HIV-1 Vpu is dispensable for counteraction of CD317.

Sebastian Bolduan1, Jörg Votteler, Veronika Lodermeyer, Timo Greiner, Herwig Koppensteiner, Michael Schindler, Gerhard Thiel, Ulrich Schubert.   

Abstract

While the C-terminal domain of HIV-1 Vpu is critical for CD4 degradation, the transmembrane domain (TM) mediates ion channel activity, enhances virus release and is essential for counteracting CD317/Bst-2/Tetherin. Here we analyzed whether the ion channel activity of Vpu is required to antagonize CD317-mediated restriction of virion release. We examined TM-mutants of three conserved residues: the S23A mutation, which was previously shown to abrogate ion channel function, did not affect Vpu mediated augmentation of virus release. In contrast, the A14N and A18N mutation did not affect ion channel activity of Vpu, but substantially reduced its ability to support virus release and to down-regulate CD317 from the cell surface. Altogether, our data suggest that not the ion channel activity of Vpu, but its ability to remove CD317 from the cell surface is required to augment HIV-1 release.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21601230     DOI: 10.1016/j.virol.2011.04.009

Source DB:  PubMed          Journal:  Virology        ISSN: 0042-6822            Impact factor:   3.616


  21 in total

Review 1.  HIV-1 Vpu - an ion channel in search of a job.

Authors:  Klaus Strebel
Journal:  Biochim Biophys Acta       Date:  2013-07-03

2.  HIV-1 Vpu mediated downregulation of CD155 requires alanine residues 10, 14 and 18 of the transmembrane domain.

Authors:  Sebastian Bolduan; Tatjana Reif; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2014-08-09       Impact factor: 3.616

Review 3.  Various plus unique: Viral protein U as a plurifunctional protein for HIV-1 replication.

Authors:  Andrew Soper; Guillermo Juarez-Fernandez; Hirofumi Aso; Miyu Moriwaki; Eri Yamada; Yusuke Nakano; Yoshio Koyanagi; Kei Sato
Journal:  Exp Biol Med (Maywood)       Date:  2017-01-01

4.  FRET Analysis of the Promiscuous yet Specific Interactions of the HIV-1 Vpu Transmembrane Domain.

Authors:  Gregory B Cole; Sean E Reichheld; Simon Sharpe
Journal:  Biophys J       Date:  2017-11-07       Impact factor: 4.033

5.  The intraviral protein interaction network of hepatitis C virus.

Authors:  Nicole Hagen; Karen Bayer; Kathrin Rösch; Michael Schindler
Journal:  Mol Cell Proteomics       Date:  2014-05-05       Impact factor: 5.911

6.  HIV-1 Vpu affects the anterograde transport and the glycosylation pattern of NTB-A.

Authors:  Sebastian Bolduan; Philipp Hubel; Tatjana Reif; Veronika Lodermeyer; Kristin Höhne; Joëlle V Fritz; Daniel Sauter; Frank Kirchhoff; Oliver T Fackler; Michael Schindler; Ulrich Schubert
Journal:  Virology       Date:  2013-03-22       Impact factor: 3.616

Review 7.  Viral miniproteins.

Authors:  Daniel DiMaio
Journal:  Annu Rev Microbiol       Date:  2014-04-10       Impact factor: 15.500

8.  Novel Acylguanidine-Based Inhibitor of HIV-1.

Authors:  Philip Mwimanzi; Ian Tietjen; Scott C Miller; Aniqa Shahid; Kyle Cobarrubias; Natalie N Kinloch; Bemuluyigza Baraki; Jonathan Richard; Andrés Finzi; David Fedida; Zabrina L Brumme; Mark A Brockman
Journal:  J Virol       Date:  2016-09-29       Impact factor: 5.103

9.  Human immunodeficiency virus type 1 Vpu and cellular TASK proteins suppress transcription of unintegrated HIV-1 DNA.

Authors:  Nkiruka Emeagwali; James E K Hildreth
Journal:  Virol J       Date:  2012-11-19       Impact factor: 4.099

10.  The HIV-1 Vpu viroporin inhibitor BIT225 does not affect Vpu-mediated tetherin antagonism.

Authors:  Björn D Kuhl; Vicky Cheng; Daniel A Donahue; Richard D Sloan; Chen Liang; John Wilkinson; Mark A Wainberg
Journal:  PLoS One       Date:  2011-11-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.